---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-010855"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2022-05-27T23:59:59+00:00"
generated_at: "2026-06-25T06:13:42.357293+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# KalVista director Daniel Soland resigns; Patrick Treanor appointed to board

## Summary
- Daniel Soland resigned from board and committees effective May 25, 2022; not due to any disagreement with the Company.
- Patrick Treanor appointed as Class II director effective May 26, 2022, term expiring at 2024 annual meeting.
- Treanor to receive initial option for 17,000 shares, $42,500 annual cash retainer, and annual option for 10,000 shares after one year.
- Treanor determined independent under NASDAQ rules; will execute standard indemnification agreement.

## SEC filing metadata
- accession: 0000950170-22-010855
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2022-05-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017022010855/0000950170-22-010855-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017022010855/kalv-20220525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-010855
- JSON: https://secwatch.observer/filing/0000950170-22-010855.json
- Plain text: https://secwatch.observer/filing/0000950170-22-010855.txt

## Key facts
- Executive change
  Patrick Treanor was appointed as Director at KalVista Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: On May 26, 2022 upon the recommendation of the Nominating and Governance Committee of the Board, the Board approved the appointment of Patrick Treanor (“ Mr. Treanor ”) to the Board effective immediately, to serve until his successor is duly elected and qualified, or until his death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000095017022010855/0000950170-22-010855-index.htm
- Executive change
  Daniel Soland resigned as Director at KalVista Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: Effective as of May 25, 2022, Daniel Soland resigned from his position on the Board of Directors (the “ Board ”) of KalVista Pharmaceuticals, Inc. (the “ Company ”) and all committees thereof.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000095017022010855/0000950170-22-010855-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.